DXCM:NGS-DexCom Inc. (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 134.56

Change

-1.58 (-1.16)%

Market Cap

USD 5.94B

Volume

2.55M

Analyst Target

USD 475.06
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

DexCom Inc designs, develops and commercializes continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
PODD Insulet Corporation

+1.57 (+0.66%)

USD 16.40B
BRKR Bruker Corporation

+1.46 (+2.19%)

USD 9.94B
MASI Masimo Corporation

-2.58 (-2.26%)

USD 6.03B
TMDX TransMedics Group Inc

+10.02 (+6.42%)

USD 5.04B
PRCT Procept Biorobotics Corp

-0.18 (-0.22%)

USD 4.00B
AXNX Axonics Modulation Technologie..

+0.53 (+0.77%)

USD 3.51B
QDEL Quidel Corporation

N/A

USD 3.06B
TNDM Tandem Diabetes Care Inc

+1.81 (+4.24%)

USD 2.88B
LIVN LivaNova PLC

+0.16 (+0.31%)

USD 2.64B
NARI Inari Medical Inc

-0.54 (-1.22%)

USD 2.61B

ETFs Containing DXCM

SDG iShares MSCI Global Impac.. 1,000.00 % 0.49 %

+0.81 (+0.76%)

USD 0.24B
CYBG:LSE VanEck Bionic Engineering.. 9.88 % 0.00 %

+0.12 (+0.76%)

N/A
SANE 6.79 % 0.00 %

N/A

N/A
CIB0:XETRA VanEck Bionic Engineering.. 6.54 % 0.00 %

+0.14 (+0.76%)

USD 6.36M
CURE:XETRA VanEck Genomics and Healt.. 6.37 % 0.00 %

+0.26 (+0.76%)

N/A
DIP 4.61 % 0.00 %

N/A

N/A
FDHT:XETRA Fidelity Digital Health U.. 4.55 % 0.00 %

+0.04 (+0.76%)

N/A
EKG First Trust Nasdaq Lux Di.. 4.52 % 0.00 %

+0.21 (+0.76%)

USD 2.48M
EDOC:AU BetaShares Digital Health.. 4.39 % 0.00 %

-0.01 (0.76%)

N/A
UMDV:SW iShares US Medical Device.. 4.00 % 0.00 %

N/A

N/A
SNSG:LSE Global X Internet of Thin.. 3.78 % 0.00 %

+0.19 (+0.76%)

USD 2.18M
SNSR Global X Internet of Thin.. 3.77 % 0.69 %

+0.73 (+0.76%)

USD 0.24B
SN5R:XETRA Global X Internet of Thin.. 3.61 % 0.00 %

+0.27 (+0.76%)

USD 3.06M
SNSR:SW Global X Internet of Thin.. 3.61 % 0.00 %

+0.23 (+0.76%)

USD 2.20M
BFIT 0.00 % 0.50 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.56 (+0.76%)

N/A
LNGR 0.00 % 0.50 %

N/A

N/A
GDNA 0.00 % 0.00 %

N/A

N/A
SLIM 0.00 % 0.50 %

N/A

N/A
DBPD:F Xtrackers - ShortDAX x2 D.. 0.00 % 0.00 %

-0.03 (0.76%)

N/A
IMCG iShares Morningstar Mid-C.. 0.00 % 0.00 %

+1.18 (+0.76%)

N/A
CVGB:LSE VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 2.24M
CAVE:LSE VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.44% 74% C 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.44% 74% C 76% C+
Trailing 12 Months  
Capital Gain 13.41% 78% C+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.41% 78% C+ 72% C
Trailing 5 Years  
Capital Gain 383.25% 95% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 383.25% 95% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 38.27% 83% B 88% B+
Dividend Return 38.27% 83% B 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 64.27% 47% F 25% F
Risk Adjusted Return 59.54% 94% A 86% B+
Market Capitalization 5.94B 100% F 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 103.24 20% 11%
Price/Book Ratio 24.86 8% 4%
Price / Cash Flow Ratio 68.59 4% 4%
Price/Free Cash Flow Ratio 55.96 6% 4%
Management Effectiveness  
Return on Equity 25.78% 97% 92%
Return on Invested Capital 9.97% 88% 79%
Return on Assets 6.41% 93% 89%
Debt to Equity Ratio 117.67% 23% 19%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.